Compare Quest Diagnostics Inc (DGX) vs Kingsoft Cloud Holdings Limited (KC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Kingsoft Cloud Holdings Limited — how do they compare? Quest Diagnostics Inc trades at $229.99 (market cap $25.48B), while Kingsoft Cloud Holdings Limited trades at $9.26 (market cap $2.71B). The key difference: Quest Diagnostics Inc is far larger — about 9.4× Kingsoft Cloud Holdings Limited's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Kingsoft Cloud Holdings Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Kingsoft Cloud Holdings Limited for 12 Days on average.
| DGX | KC | |
|---|---|---|
Market Cap | $25.48B | $2.71B |
Volume | 941,866 | 1,993,765 |
Sector | Health | Technology |
52-Week High | $247.45 | $18.21 |
52-Week Low | $173.49 | $8.58 |
Typical Hold Time | 56 Days | 12 Days |
Enterprise Value | $31.23B | $3.03B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
Kingsoft Cloud (KC) trades at $9.23 with no recent price movement. The stock shows bearish technical signals with support at $8-9 levels. Fundamentally, while revenue grew to $9.56B in 2025, the company reported a net loss of $936M with negative profit margins. Recent Q2 2026 results beat expectations with 30.8% revenue growth and improved gross margins driven by AI cloud services expansion.
Analyst consensus remains positive with 70% buy ratings and 60.3% upside potential, but technical indicators suggest caution. Key risks include ongoing profitability challenges and competitive pressures in China's cloud market. The AI partnership with Xiaomi provides growth catalyst potential, though execution risks persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Kingsoft Cloud Holdings Limited
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →
